Current views on obesity

American Journal of Medicine

Volumn 100, Issue 2, 1996, Pages 230-236

  Stunkard, Albert J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; BENZPHETAMINE; DEXFENFLURAMINE; FENFLURAMINE; MAZINDOL; METHAMPHETAMINE; OBENIX; PHENTERMINE; PHENTERMINE RESIN; PHENYLPROPANOLAMINE; SIBUTRAMINE; TEPANOL; UNCLASSIFIED DRUG; ZANTRYL;

ARTICLE; BEHAVIOR THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DIET RESTRICTION; DRUG INDICATION; EXERCISE; GASTROPLASTY; HUMAN; OBESITY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0030063440     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)89464-8     Document Type: Review

References (82)

1. Council on Scientific Affairs of the American Medical Association. Treatment of obesity in adults. JAMA. 1988;260:2547-2551.
2. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med. 1993;119: 655-660.
3. Pi-Sunyer FX. Health implications of obesity. Am J Clin Nutr. 1991;53: 1595S-1603S.
4. National Institutes of Health. Health Implications of Obesity: Consensus Development Conference Statement. Volume 5, Number 9. Bethesda: National Institutes of Health; 1985.
5. Bray GA. Pathophysiology of obesity. Am J Clin Nutr. 1992;55(suppl): 488S-494S.
6. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA. 1993;270:2207-2212.
7. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-977.
8. Sharp JT, Barrocas M, Chokroverty S. The cardiorespiratory effects of obesity. Clin Chest Med. 1980;1:103-118.
9. Kral JG. Morbid obesity and related health risks. Ann Intern Med. 1985;103: 1043-1047.
10. Björntorp P. Classification of obese patients and complications related to the distribution of surplus fat. Am J Clin Nutr. 1987;45:1120-1125.
11. Després J-P, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis, 1990;10: 497-511.
12. Atkinson RL. Proposed standards for judging the success of the treatment of obesity. Ann Intern Med. 1993;119:677-680.
13. Drenick EJ, Johnson D. Weight reduction by fasting and semistarvation in morbid obesity: long-term follow-up. Int J Obes. 1978;2:123-132.
14. Goodrick GK, Foreyt JP. Why treatments for obesity don't last. J Am Diet Assoc. 1991;91:1243-1247.
15. Prentice AM. Effects of weight cycling on body composition. Am J Clin Nutr. 1992;56(suppl 1):209S-216S.
16. Reed GW, Hill JO. Weight cycling: a review of the animal literature. Obes Res. 1993;1:392-402.
17. Wing RR. Weight cycling in humans: a review of the literature. Ann Behav Med. 1992;14:113-119.
18. Wadden TA, Bartlett S, Letizia KA, et al. Relationship of dieting history to resting metabolic rate, body composition, eating behavior, and subsequent weight loss. Am J Clin Nutr. 1992;56:203S-208S.
19. Jeffery RW, Wing RR, French SA. Weight cycling and cardiovascular risk factors in obese men and women. Am J Clin Nutr. 1992;55:641-644.
20. Higgins M, D'Agostino R, Kannel W, Cobb J. Benefits and adverse effects of weight loss: observations from the Framingham Study. Ann Intern Med. 1993;119:758-763.
21. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among U.S. adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205-211.
22. Butler RN. The challenge of geriatric medicine. In: Wilson JD, Braunwald E, Isselbacher KJ, et al, eds. Harrison's Principles of Internal Medicine. 12th ed. New York: McGraw-Hill; 1991:16-19.
23. Bray GA, Gray DS. Treatment of obesity: an overview. Diabetes Metab Rev. 1988;4:653-659.
24. Blackburn GL. Comparison of medically supervised and unsupervised approaches to weight loss and control. Ann Intern Med. 1993;119:714-718.
25. Krai JG, Sjöström LV, Sullivan MBE. Assessment of quality of life before and after surgery. Am J Clin Nutr. 1992;55:611S-614S.
26. Yanovski SZ. A practical approach to treatment of the obese patient. Arch Fam Med. 1993;2:309-316.
27. Gortmaker SL, Must A, Perrin JM, et al. Social and economic consequences of overweight in adolescence and young adulthood, NEJM. 1993;329: 1008-1012.
28. Stunkard AJ, Sørensen TIA. Obesity and socioeconomic status - a complex relation. NEJM. 1993;329:1036-1037.
29. Bray GA. Obesity: historical development of scientific and cultural ideas. Int J Obes. 1990;14:909-926.
30. Blumberg P, Mellis LP. Medical students' attitudes toward the obese and the morbidly obese. Int J Eat Disord. 1985;4:169-175.
31. Maddox GL, Anderson CF, Bogdonoff MD. Overweight as a problem of medical management in a public outpatient clinic. Am J Med Sci. 1966;252: 394-403.
32. Cade J, O'Connell S. Management of weight problems; and obesity: knowledge, attitudes and current practice of general practitioners. Br J Gen Pract. 1991;41:147-150.
33. Price JH, Desmond SM, Krol RA, et al. Family practice physicians' beliefs, attitudes, and practices regarding obesity. Am J Prev Med. 1987;3:339-345.
34. Frank A. Futility and avoidance: medical professionals in the treatment of obesity. JAMA. 1993;269:2132-2133.
35. Bray GA, York B, DeLany J. A survey of the opinions of obesity experts on the causes and treatment of obesity. Am J Clin Nutr. 1992;55(suppl): 151S-154S.
36. Murphree D. Patient attitudes toward physician treatment of obesity. J of Fam Prac. 1994;38:45-48.
37. Rand CSW, Macgregor AMC. Successful weight loss following obesity surgery and perceived liability of morbid obesity. Int J Obes. 1991;15: 577-579.
38. National Institutes of Health. Methods for voluntary weight loss and control: Technology Assessment Conference statement. Nutr Rev. 1992:50:340-345.
39. Wadden TA. Etiology and treatment of obesity. Curr Opin Psychiatry. 1993;6:816-820.
40. Bray GA. Genetic, hypothalamic and endocrine features of clinical and experimental obesity. In: Swaab DF, Hofman MA, Mirmiran M, et al, eds. Progress in Brain Research, Vol 93. Amsterdam: Elsevier Science Publishers; 1992:333-341.
41. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425-432.
42. Stunkard AJ. Genetic contributions to human obesity. In: McHugh PR, McKusick VA, eds. Genes, Brain and Behavior. New York: Raven Press; 1991:205-218.
43. Bouchard C. The Genetics of Obesity. Boca Raton: CRC Press; 1994.
44. Vogler GP, Sørensen TIA, Stunkard AJ, et al. Influences of genes and shared family environment on adult body mass index assessed by a comprehensive path model in an adoption study. Int J Obesity. 1995;19:40-45.
45. Sobal J, Stunkard AJ. Socioeconomic status and obesity: a review of the literature. Psychol Bull. 1989;105:260-275.
46. Bandini LJ, Schoeller DA, Cyr HYN, Dietz WH. Validity of reported energy intake in obese and nonobese adolescents. Am J Clin Nutr. 1990;52:421-425.
47. Lichtman SW, Pisarski K, Berman ER. Discrepancy between self-reported and actual calorie intake and excercise in obese subjects. NEJM. 1992;327: 1893-1898.
48. Black AE, Prentice AM, Golding GR, et al. Measurements of total energy expenditure provide insights into the validity of dietary measurements of energy intake. J Am Diet Assoc. 1993;93:572-579.
49. Flatt JP, Ravussin E, Acheson KJ, et al. Effects of dietary fat on postprandial substrate oxidation and on carbohydrate and fat balances. J Clin Invest. 1985;76:1019-1024.
50. McGinnis JM. The public health burden of a sedentary life style. Med Sci Sports Exerc. 1992;24:5196-5200.
51. Kanders BS, Blackburn GL. Reducing primary risk factors by therapeutic weight loss. In: Wadden TA, Van Itallie TB, eds. Treatment of the Seriously Obese Patient. New York: Guilford Press; 1992:213-230.
52. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes. 1992;16:397-415.
53. Institute of Medicine. Weighing the Options. Washington, DC: National Academy of Sciences Press, 1995.
54. Brownell KD, Wadden TA. Etiology and treatment of obesity: understanding a serious, prevalent, and refractory disorder. J Consult Clin Psychol. 1992;60:505-517.
55. Wilson GT, O'Leary KD. Principles of Behavior Therapy. Englewood Cliffs: Prentice Hall; 1980.
56. Wing RR. Behavioral treatment of severe obesity. Am J Clin Nutr. 1992;55 (suppl):545S-551S.
57. Pi-Sunyer FX. Exercise in the treatment of obesity. In: Frankle RT, Yang MU, eds. Obesity and Weight Control: The Health Professional's Guide to Understanding and Treatment. Rockville, Maryland: Aspen Publishers, Inc.; 1988:241-255.
58. Blair SN. Evidence for success of exercise in weight loss and control. Ann Intern Med. 1993;119:702-706.
59. Foreyt JP, Goodrick GK. Evidence for success of behavior modification in weight loss and control. Ann Intern Med. 1993;119:698-701.
60. Pavlou KN, Krey S, Steffee WP. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr. 1989;49: 1115-1123.
61. Bjorvell J, Rössner S. A ten-year follow-up of weight change in severely obese subjects treated in a combined behavioural modification programme. Int J Obes. 1992;16:623-625.
62. Wadden TA, Van Itallie TB, Blackburn GL. Responsible and irresponsible use of very-low-calorie diets in the treatment of obesity. JAMA. 1990;263: 83-85.
63. Wadden TA, Van Itallie TB, eds. Treatment of the Seriously Obese Patient. New York: Guilford Press; 1992.
64. Goldstein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr. 1994;60:647-657.
65. Hirsch J. Comments on "Long-Term Weight Loss: the Effect of Pharmacologic Agents," by DJ Goldstein and JH Potvin. Am J Clin Nutr. 1994;60:658-659.
66. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med. 1993;119:707-713.
67. Bray GA. Barriers to the treatment of obesity. Ann Intern Med. 1991;115: 152-153.
68. Richard BW, Lasagna L. Anorectic drugs: drug policy making at the state level. J Clin Pharmacol. 1988;28:395-400.
69. Stallone DD, Stunkard AJ. Long-term use of appetite suppressant medication: rationale and recommendations. Drug Devel Res. 1992;26:1-20.
70. Bray GA. A case for drug treatment of obesity. Hosp Pract. 1994;29: 53,57,58,60,63.
71. American Medical Association. Drugs used in obesity. Drug Evaluations. Chicago: American Medical Association, 1994;6:1-6,16.
72. Craighead LW, Stunkard AJ, O'Brien R. Behavior therapy and pharmacotherapy of obesity. Arch Gen Psychiatry. 1981;38:763-768.
73. Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study V (weeks 190 to 210): follow-up of participants after cessation of medication. Clin Pharmacol Ther. 1992;51:615-618.
74. McTavish D, Heel R. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs. 1992;43:713-733.
75. Guy-Grand B, Apfelbaum M, Crepaldi G, et al. International trial of long-term dexfenfluramine in obesity. Lancet. 1989;i:1142-1144.
76. Weintraub M, Rubio A, Golik A, et al. Sibutramine in weight control: a doseranging, efficacy study. Clin Pharmacol Ther. 1991;50:330-337.
77. Hauptman JB, Jenuet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr. 1992;55(suppl):309S-313S.
78. Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes. 1993;17:241-244.
79. National Institutes of Health. Gastrointestinal surgery for severe obesity: Consensus Development Conference statement. Ann Intern Wed. 1991;115: 956-961.
80. Pories WJ, MacDonald KG Jr., Morgan EJ, et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr. 1992;55: 582S-585S.
81. Kral JG. Overview of surgical techniques for treating obesity. Am J Clin Nutr. 1992;55:552S-555S.
82. Stunkard AJ, Stinnett JL, Smoller JW. Psychological and social aspects of the surgical treatment of obesity. Am J Psychiatry. 1986;143:412-429.